Amarantus Bioscience Holdings

Amarantus BioScience Holdings, Inc. is a biopharmaceutical company, which engages in developing therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, and diagnostics in neurology. The company is headquartered in San Francisco, California. The company went IPO on 2008-09-29. The firm is focused on developing therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology and regenerative medicine. The firm owns or has licenses to various product candidates in the biopharmaceutical healthcare industry. The company has acquired the rights to the engineered skin substitute program (ESS), a regenerative medicine-based approach for treating severe burns with full-thickness autologous skin grown in tissue culture that is being pursued by Company’s wholly owned subsidiary Cutanogen Corporation. The Company’s wholly owned subsidiary MANF Therapeutics, Inc. owns intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor (MANF). MANF Therapeutics, Inc. is developing MANF-based products as treatments for ophthalmological disorders.